当前位置:首页>产品中心>单抗/多抗>Research Grade Albinterferon alfa-2b|Albinterferon alfa-2b(研究用级别)(靶标:白蛋白干扰素α-2b)

Research Grade Albinterferon alfa-2b|Albinterferon alfa-2b(研究用级别)(靶标:白蛋白干扰素α-2b)

  • 货号:RB9THB823026
  • 价格:面议
  • 点击:482
   一键复制产品信息 复制成功!

产品介绍

产品参数

形态Liquid
宿主种属Human
抗体亚型Fusion - ALB (albumin, human serum albumin, HSA) 2
纯度>95% purity as determined by SDS-PAGE.
纯化方式Purified by ion exchange chromatography.
浓度0.5mg/ml
内毒素水平Please contact the lab for this information.
应用ELISA, Functional assay, Research in vivo
种属反应性Human
靶标IFNAR1/IFNAR2
储存缓冲液0.01M PBS, pH 7.4.
稳定性和储存Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
表达系统Mammalian Cells
登录号P17181, P48551
背景信息Albinterferon alfa-2B (alb-IFN) is a recombinant protein consisting of interferon alfa-2b genetically fused to human albumin. Albinterferon alfa-2B can be used for the research of chronic hepatitis C.
• The Role of Structure in the Biology of Interferon Signaling., PMID:33281831
• Specific activation of embryonic IFNAR1 and endometrial IFNAR2 induced by embryonic IFNτ directs normal uterine fate for bovine early implantation., PMID:35907379
• Proximal protein landscapes of the type I interferon signaling cascade reveal negative regulation by PJA2., PMID:38802340
• IFNAR2 Is Required for Anti-influenza Immunity and Alters Susceptibility to Post-influenza Bacterial Superinfections., PMID:30473701
• Construction of an IFNAR1 knockout MDBK cell line using CRISPR/Cas9 and its effect on bovine virus replication., PMID:39100665
• Synthetic mimetics assigned a major role to IFNAR2 in type I interferon signaling., PMID:36118237
• Structure-function of type I and III interferons., PMID:38608537
• Triggering ubiquitination of IFNAR1 protects tissues from inflammatory injury., PMID:24480543
• Mechanism of Rhinovirus Immunity and Asthma., PMID:34691038
• Structural basis for the recognition of IFNAR1 by the humanized therapeutic monoclonal antibody QX006N for the treatment of systemic lupus erythematosus., PMID:38649079
别名Alb-IFNA2R23(608), Albumin-interferonalpha-2b, JoulferonZALBIN™
备注For research use only. Not suitable for clinical or therapeutic use.
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Isatuximab Non-Neutralizing Recombinant Antibody |抗艾沙妥昔单抗非中和重组抗体(靶标:艾沙妥昔单抗非中和抗体) 363
Anti-Isatuximab Non-Neutralizing Recombinant Antibody |抗艾沙妥昔单抗非中和重组抗体(靶标:艾沙妥昔单抗非中和抗体) 587
Anti-Isatuximab Neutralizing Recombinant Antibody |抗艾沙妥昔单抗中和重组抗体(靶标:艾沙妥昔单抗中和抗体) 472
Anti-Isatuximab Neutralizing Recombinant Antibody |抗艾沙妥昔单抗中和重组抗体(靶标:艾沙妥昔单抗中和抗体) 322
Anti-Isatuximab Neutralizing Recombinant Antibody |抗艾沙妥昔单抗中和重组抗体(靶标:艾沙妥昔单抗中和抗体) 283
Anti-Urelumab Non-Neutralizing Recombinant Antibody |抗乌瑞鲁单抗非中和重组抗体(靶标:乌瑞鲁单抗非中和抗体) 551
Anti-Urelumab Non-Neutralizing Recombinant Antibody |抗乌瑞鲁单抗非中和重组抗体(靶标:乌瑞鲁单抗非中和抗体) 565
Anti-Urelumab Neutralizing Recombinant Antibody |抗乌瑞鲁单抗中和重组抗体(靶标:乌瑞鲁单抗中和抗体) 602
Anti-Urelumab Neutralizing Recombinant Antibody |抗乌瑞鲁单抗中和重组抗体(靶标:乌瑞鲁单抗中和抗体) 575
Anti-Urelumab Neutralizing Recombinant Antibody |抗乌瑞鲁单抗中和重组抗体(靶标:乌瑞鲁单抗中和抗体) 521
Anti-Risankizumab Neutralizing Recombinant Antibody |抗瑞莎珠单抗中和重组抗体(靶标:瑞莎珠单抗中和抗体) 314
Anti-Risankizumab Neutralizing Recombinant Antibody |抗瑞莎珠单抗中和重组抗体(靶标:瑞莎珠单抗中和抗体) 427
Anti-Risankizumab Neutralizing Recombinant Antibody |抗瑞莎珠单抗中和重组抗体(靶标:瑞莎珠单抗中和抗体) 629
Anti-Risankizumab Neutralizing Recombinant Antibody |抗瑞莎珠单抗中和重组抗体(靶标:瑞莎珠单抗中和抗体) 312
Anti-Ranibizumab Non-Neutralizing Recombinant Antibody |抗雷珠单抗非中和重组抗体(靶标:雷珠单抗非中和抗体) 508
Anti-Ranibizumab Non-Neutralizing Recombinant Antibody |抗雷珠单抗非中和重组抗体(靶标:雷珠单抗非中和抗体) 403
Anti-Ranibizumab Non-Neutralizing Recombinant Antibody |抗雷珠单抗非中和重组抗体(靶标:雷珠单抗非中和抗体) 503
Anti-Ranibizumab Neutralizing Recombinant Antibody |抗雷珠单抗中和重组抗体(靶标:雷珠单抗中和抗体) 373
Anti-Ranibizumab Neutralizing Recombinant Antibody |抗雷珠单抗中和重组抗体(靶标:雷珠单抗中和抗体) 506
Anti-Ranibizumab Neutralizing Recombinant Antibody |抗雷珠单抗中和重组抗体(靶标:雷珠单抗中和抗体) 298
总计 33037 个记录,共 1652 页,当前第 1645 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00